SINOTHERAPEUTICS: Enzalutamide tablets have received approval number from the U.S. FDA

According to the Zhitong Finance APP, SINOTHERAPEUTICS announced that the company has received notification from the U.S. Food and Drug Administration (referred to as "U.S. FDA") that its abbreviated new drug application (referred to as "ANDA," which is the U.S. generic drug application) for enzalutamide tablets has been temporarily approved. Enzalutamide tablets are an androgen receptor inhibitor, and the approved indications are: castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer

According to the Zhitong Finance APP, SINOTHERAPEUTICS (688247.SH) announced that the company has received notification from the U.S. Food and Drug Administration (referred to as "U.S. FDA") that its abbreviated new drug application (referred to as "ANDA," i.e., U.S. generic drug application) for Enzalutamide tablets has been temporarily approved. Enzalutamide tablets are an androgen receptor inhibitor, and the approved indications are: castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer